Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Gender-Affirming Estrogen Therapy on Drug Metabolism
NCT05469204Phase 4Completed
- Sponsor
- University of Washington
- Start
- Nov 2022
- Primary completion
- Jul 2025
- Modality
- Hormone, Biologic
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of estradiol in gender dysphoria (GD), sponsored by University of Washington. Primary endpoints: Midazolam Area Under the Curve Ratio (treatment/control) and Digoxin Renal Clearance Ratio (treatment/control). Started Nov 2022; status: completed.
02
Drugs
estradiol
03
Conditions
gender dysphoria (GD)
Beyond the preview
Go deeper on NCT05469204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05469204.